Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- DNLI
- Price
- 19.28
- Stock movement up
- +0.51 (2.72%)
- Company name
- Denali Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.01B
- Ent value
- 3.05B
- Price/Sales
- -
- Price/Book
- 3.25
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 4.46%
- 1 year return (CAGR)
- -9.53%
- 3 year return (CAGR)
- -13.73%
- 5 year return (CAGR)
- -23.36%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
DNLI does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 3.25 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 156.16M |
| EPS (TTM) | -2.89 |
| FCF per share (TTM) | -2.40 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -105.00M |
| Operating income (TTM) | -547.82M |
| Net income (TTM) | -498.74M |
| EPS (TTM) | -2.89 |
| EPS (1y forward) | -2.94 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 90.96M |
| Net receivables | 1.90M |
| Total current assets | 882.60M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 123.21M |
| Total assets | 1.06B |
| Accounts payable | 6.75M |
| Short/Current long term debt | 44.40M |
| Total current liabilities | 90.15M |
| Total liabilities | 129.42M |
| Shareholder's equity | 926.20M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -397.78M |
| Capital expenditures (TTM) | 15.83M |
| Free cash flow (TTM) | -413.60M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -53.85% |
| Return on Assets | -47.25% |
| Return on Invested Capital | -53.32% |
| Cash Return on Invested Capital | -44.22% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 18.73 |
| Daily high | 19.63 |
| Daily low | 18.65 |
| Daily Volume | 1.86M |
| All-time high | 93.56 |
| 1y analyst estimate | 32.86 |
| Beta | 1.02 |
| EPS (TTM) | -2.89 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 2 Mar 2026 |
Downside potential
Loading...
Downside potential data
| DNLI | S&P500 | |
| Current price drop from All-time high | -79.39% | -1.82% |
| Highest price drop | -87.74% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -50.45% | -10.84% |
| Avg time to new high | 47 days | 12 days |
| Max time to new high | 1293 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.01B
Marketcap category
Mid-cap
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Employees
517
Investor relations
-
SEC filings
CEO
Ryan J. Watts
Country
USA
City
San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page